Alpha Teknova, Inc.
TKNOHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeAlpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. At a $369.4M market cap, Alpha Teknova, Inc. ranks as a small-cap company within healthcare. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Market Cap
$369.4M
Beta
0.73
P/E (TTM)
—
P/E (Fwd)
-36.21
EPS (TTM)
$-0.31
EPS (Fwd)
$-0.19
ROE
-24.2%
ROA
-9.3%
Cash
$17.4M
Total Debt
$27.4M
Free CF
-$735,250
52W Change
74.8%
Annual Financials
Cash vs Debt
Where TKNO stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, TKNO finished 73.85% above its 150-day moving average ($4.13) and 72.60% above its 200-day moving average ($4.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TKNO overbought or oversold?
At the September 1, 2026 close, TKNO's RSI(14) was 52.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $17.4M in cash, though total debt stands at $27.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$735K, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -24.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $41.4M (2022) to $40.5M (2025).
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Alpha Teknova, Inc. and its sector.